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Simple Summary: Cancer is as common amongst pets as it in humans. Chemotherapy can be
integrated into treatment regimes for terminally ill pets to attempt to shrink tumours to extend life
expectancy, but it does not cure cancer and it can have negative side effects including vomiting,
depression and behavioral changes. To date, little research has been undertaken to explore owners’
decisions whether or not to treat their animals with chemotherapy. Seventy-eight dog and cat
owners completed an online questionnaire to determine if they would opt for chemotherapy if
their pet was diagnosed with cancer, and asked how they thought their pet’s quality of life would
be affected. Fifty-eight percent of respondents would not use chemotherapy largely due to their
previous experience of it. Seventy-two percent over estimated pet survival time post chemotherapy,
with most people believing it would lead to remission or a cure. Owners expected their pets to be
less active, sleep more and play less, reducing their quality of life. Common side effects associated
with chemotherapy were not rated as acceptable. The results suggest pet owners would benefit from
an increased understanding of the positive and negative impacts of chemotherapy when initially
discussing treatment options with the veterinary team.
Abstract: Chemotherapy is a commonly integrated treatment option within human and animal
oncology regimes. Limited research has investigated pet owners’ treatment decision-making in
animals diagnosed with malignant neoplasia. Dog and cat owners were asked to complete an online
questionnaire to elucidate factors which are key to the decision making process. Seventy-eight
respondents completed the questionnaire in full. Fifty-eight percent of pet owners would not elect to
treat pets with chemotherapy due to the negative impact of the associated side effects. Seventy-two
percent of respondents over estimated pet survival time post chemotherapy, indicating a general
perception that it would lead to remission or a cure. Vomiting was considered an acceptable side
effect but inappetence, weight loss and depression were considered unacceptable. Owners did expect
animals’ to be less active, sleep more and play less, but common side effects were not rated as
acceptable despite the potential benefits of chemotherapy. Based on the results, veterinary teams
involved with oncology consultations should establish if clients have prior experience of cancer
treatments and their expectations of survival time. Quality of life assessments should also be
implemented during initial oncology consultations and conducted regularly during chemotherapy
courses to inform client decision making and to safe guard animal welfare.
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1. Introduction
Chemotherapy is a commonly integrated treatment option within human and animal oncology
regimes [1–3] which aims to reduce the growth of tumours and spread of malignant neoplastic
cells. It is defined as the ingestion or injection of cytotoxic drugs to destroy neoplastic or cancer
cells [4]. In animals five cancer treatment approaches are taken: palliative care, surgery, chemotherapy
(±surgery), radiotherapy or euthanasia [5]. Within veterinary practice, the treatment approach for
animals diagnosed with malignant and terminal neoplasia will be informed by discussion with the
veterinary team including an overview of therapeutic options, their side effects and benefits, prognosis
and survival time, and impact on the pet’s quality of life. Despite this, research suggests chemotherapy
is often elected for by pet owners due to their prior experience or knowledge of its positive (perceived
effective) application in human cancer treatment [6,7].
Neoplasia affects approximately 0.02% dogs and 0.01% cats in the UK per annum [8,9].
The prognosis for animals suffering from malignant neoplasia varies upon the clinical approach
taken but generally is poor. For example, the average survival time post-diagnosis for dogs with
lymphoma without treatment is 4 to 6 weeks [10]. Research has shown this can be extended with
treatment, for example Wang et al. [11] reported survival times of between 5 and 7.5 months with
treatment [11]. It should however be noted that survival times will vary between individuals, the type
of malignancy present and the oncology regime undertaken.
The decision making process during oncology treatment can lead to ethical dilemmas for owners
and the veterinary team. The status of animals in society is inconsistent, ranging from owners who
treat their pets as family members [12] and will spare no expense upon them, to others who will
abandon animals when they become an inconvenience [13]. The Royal College of Veterinary Surgeon’s
Code of Professional Conduct requires veterinary surgeons to provide owners of animals undergoing
chemotherapy with an outline of all potential treatment options, associated fees and side effects,
and the subsequent prognosis for their pet [14]. The priority for the veterinary team is to safeguard the
welfare of their animal patient but they also need to support the owner/s through an emotive decision.
However, the owner ultimately has the responsibility to make a decision which safeguards the welfare
of their pet [15] and as such needs to understand the full implications of their choice. Within human
medicine, terminally ill patients and their care givers often feel doctors have ‘given up’ on them if
chemotherapy is not offered as treatment option or is withdrawn during the latter stages of palliative
care [16]. A similar scenario may exist within veterinary medicine but this has not been investigated to
date. Interestingly, Giuffrida and Kerrigan [17] report that the owners of terminally ill pets value the
quality of life of their pet over extended survival times. This suggests that an open and transparent
approach from the veterinary team when discussing with the owner the risks, benefits, impact of
the treatment involved and the outcome with consideration of quality of life, is essential to support
informed consent for subsequent treatment protocols or if they decide to opt for euthanasia [18–20].
Chemotherapy Treatment
The use of chemotherapy within therapeutic oncology programmes in the veterinary sector is
becoming more commonplace [21]. Despite this no large scale studies to date have investigated the
prevalence, incidence or severity of potential side-effects associated with the treatment in animals,
or if clinical symptoms reported as side effects may be due to alternative aetiologies. Therefore
owners may refer to human medicine and their own experiences to judge the impact of chemotherapy
protocols within their pets. A full review of the impact of chemotherapy on survival times in animals
is beyond the scope of this review due to the range of different protocols, multitude of cancer types
and confounding factors which can affect prognosis. Illustrations of survival times are provided
however readers unfamiliar with oncology are advised that these provide specific examples and do not
represent the entirety of the field. Chemotherapy has been shown to extend the lifespan of terminally ill
dogs diagnosed with malignant neoplasia on average by 185 days (histiocytic sarcoma) [22], 301 days
(appendicular osteosarcoma) [23] and 216 to 342 days (lymphoma) [24]. Similar results have been
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found in cats that have undergone chemotherapy for extranodal lymphoma recording survival times
ranging from 70 days to 749 days [25]. Surgical removal of malignant neoplastic masses without
an accompanying chemotherapy course can also exert a beneficial impact on survival, however
survival time is often reduced compared to animals with the same diagnosis who undergo surgery
and chemotherapy (mammary carcinoma) [26]. Therefore, chemotherapy is considered to extend
survival time for the terminally ill pet compared to surgical reduction alone and has a clear benefit as
part of an oncology treatment regime [27]. Weeks et al. [28] surveyed the expectations of terminally
ill patients with lung and colorectal cancer, finding 69% and 81% of patients respectively felt that
chemotherapy would cure their cancer. Prior experience of chemotherapy may influence pet owners’
decision making and although surveys suggest quality of life is of key importance [17], when faced
with losing their pet, extended survival times, which chemotherapy offers, alongside the incorrect
perception that chemotherapy could facilitate a cure, may influence owner choices.
Chemotherapy can cause detrimental side effects in animals [29] and humans [28]. The treatment
is non-discriminatory and can have a toxic effect on diseased and healthy tissue [30], resulting in
myelosuppression, gastrointestinal toxicosis and nausea in human patients [31–33]. Within dogs,
analogous side effects have been reported post chemotherapy treatment including gastrointestinal
disease, myelosuppression, cardiotoxicity, dyspnoea and neutropenia resulting in immunological
challenges predisposing patients to secondary infections [34,35]. Cognitive changes are also often
reported by human patients post chemotherapy treatment, termed “chemobrain”; symptoms include
difficulty comprehending normal tasks, lack of concentration, memory issues and lack of awareness of
what they are doing [36]. Canine patients will often vomit after treatment and are thought to experience
nausea leading to anorexia during chemotherapy [37,38]. As a result of regular emesis, patients can
experience weakness, fatigue, anaemia and fever-type symptoms which can result in weight loss.
Behavioural changes, reported within quality of life assessments in neoplasia cases [29], with pets
becoming progressively more lethargic and depressed (unresponsive, inactive and withdrawn with
altered eating and sleeping patterns) resulting in reduced interaction with their owners and the
environment which can be upsetting for owners. However it should be remembered that the remit
of chemotherapy is to shrink or prevent spread of tumours, and many of the perceived negative side
effects should be considered alongside the beneficial effect this treatment can have on prognosis and
survival time in canine and feline cancer patients.
Quality of life assessments are often employed to make judgments on an animal’s welfare
status [29,39,40]. Yeates and Main [41] advocate that a quality of life assessment should be included
by the veterinary team when considering therapeutic options for animals suffering from malignant
neoplasia. Integrating Quality of Life (QOL) assessments can inform owner decision making, to ensure
an ethical balance between quality and quantity of life is achieved, and the welfare of the animal
affected is fully considered [40,41]. The quality of life process can also provide a baseline measure for
subsequent assessments. Quality of life assessments, conducted via owner questionnaires, have been
conducted in cats [39,42] and dogs undertaking chemotherapy [43,44]. Generally, owners across species
were very perceptive to clinical changes in their pets but did not appear to demonstrate equal acuity
when identifying QOL changes. This may reflect the tool used, as many quality of life assessments
rarely progress beyond evaluation of clinical parameters and fail to integrate other qualities such as
cognition, normal functionality, and con-specific interaction within them [44].
To date, research evaluating chemotherapy use in pets has centred on retrospective reviews of
veterinary records to evaluate clinical symptoms, therapeutic approaches and subsequent survival
times in neoplastic animals. For examples refer to Finlay et al. [45] and Wright et al. [19]. Whilst this
information is critical to enable informed dialogue from the veterinary team to the client, assessment of
the factors which influence the decision making process pet owners undertake when deciding whether
to consent to a course of chemotherapy has been neglected. Therefore, this study aimed to explore
factors which may influence owners’ decision to elect to undertake chemotherapy in animals, to help
inform the approaches taken by the veterinary profession.
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2. Method
A mixed methods approach was used to survey current and previous owners of dogs or cats in
the UK, to ascertain what factors would influence the decision making process to elect to undertake
chemotherapy treatment in a terminally ill pet. Ethical approval was obtained from the University of
the West of England (Hartpury) Ethics Committee (Project Identification Code: ETHICS2016-04).
2.1. Participants
Participants were recruited via social media: Facebook and Twitter, between November 2015
and February 2016 due to the capacity for social media to acquire a large number of participants [46].
Subjects were required to be over 18 years of age and to currently own or have previously owned a cat
or dog, to be eligible for participation. No previous experience with neoplasm in terminally ill animals
or humans was essential. Only fully completed questionnaires progressed to data analysis.
2.2. Survey Design
A questionnaire was designed in Google Forms™. The questionnaire included open and closed
questions (Supplementary Materials). Likert scales were also integrated within the questionnaire to
allow participants to rank the importance of key themes surveyed. These were complemented by the
use of open questions to encourage participants to answer with unprompted responses to facilitate
a truer expression of the emotions and feelings they had on the use of chemotherapy in animals [47].
Three key themes were adapted from previous research [39,40,43] and were embedded within the
questionnaire: owner perception of the benefits and side effects of chemotherapy (Table 1), rating of
quality of life (scale 1: low to 10: high) pre, peri and post chemotherapy, and views on survival times
and life expectancy with and without chemotherapy treatment.
Table 1. Quality of life assessment questions.
Participants Were Asked to Rate if They Found the Potential Impact of Chemotherapy
in Animals, for the Questions Listed, as Acceptable or Unacceptable.
My pet does not play during chemotherapy
My pet’s activity is the same during chemotherapy
My pet sleeps more than usual during chemotherapy
My pet eats normally during chemotherapy
My pets seem depressed during chemotherapy
My pet has more good days then bad during chemotherapy
My pet trembles and shakes occasionally during chemotherapy
My pet grooms normally during chemotherapy
My pet experiences vomiting during chemotherapy
My pet drinks normal amounts during chemotherapy
My pet has diarrhoea during chemotherapy
My pet is aware and happy when I’m present during chemotherapy
My pet is less active during chemotherapy
2.3. Data Analysis
Data from completed questionnaires were transferred to Microsoft™ Excel version 2013
(Microsoft Corporation, Redmond, WA, USA). Frequency analysis of categorical data was performed
across the cohort, then data were organised by gender and age within gender to highlight any emergent
trends within the subgroups. Grounded theory analysis was applied to the narrative obtained from
open questions to enable emergent themes from the data to be recognised [48].
3. Results
A total of 78 questionnaires were completed in their entirety and went forward to analysis.
The majority of respondents were female (n = 68); these represented a variety of age ranges: 18–24 years:
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23%, 25–35 years: 26%, 36–49 years: 27% and over 50 years: 22%. Male participants (n = 10)
demonstrated an older age demographic: 18–24 years: 10%, 25–35 years: 40% and over 50 years:
50%. The majority of respondents had some prior experience of chemotherapy (female respondents:
53%; male respondents: 60%), this was within a friend or family member for 39% of female respondents
and 40% of male respondents, and in a pet for 14% of female respondents and 20% of male respondents
(Figure 1). Fifty-five percent of respondents (female respondents: 57%; male respondents: 30%) stated
they were familiar with the side effects that accompanied chemotherapy in animals, with slightly more,
57%, aware of the side effects associated with chemotherapy in human patients (female respondents:
61%; male respondents: 40%).
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Figure 1. Participants’ previous experiences with chemotherapy treatment (CT).
The majority of participants (58%) believed that the benefits of chemotherapy did not
counterbalance the impact of the potentially negative side effects which animals may experience
during treatment. However, when respondents were asked to rate the acceptability of defined side
effects and benefits of chemotherapy, mixed opinions were recorded (Figures 2 and 3, respectively).
Interestingly, respondents thought that pets’ QOL would be enhanced after chemotherapy (median
rating: 7; interquartile range (IQR): 2) compared to prior to (median rating: 5; IQR: 3) and during
treatment (median rating: 5; IQR: 3). All respondents indicated that they believed chemotherapy
would extend an animal’s life expectancy and 72% felt that chemotherapy would extend survival time
over one year (Figure 4).
Respondents expectations on the quality of life dogs and cats experience during chemotherapy
regimens varied (Figure 5). The results indicate the majority of owners wanted their animal to
retain a normal quality of life with regards to eating, drinking, behaviour and activity levels, and low
expression of known side effects associated with chemotherapy: vomiting, diarrhoea and depression.
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When asked if survival time would influence the decision to undertake chemotherapy in their pet,
a total of 52 out of 78 respondents (67%) disagreed, or strongly disagreed to the statement “I would
opt for chemotherapy treatment if my pet will live for an extra 3 months with the chemotherapy”.
Generating mixed comments such as “cancer if the lesser evil” and “months is enough time as long as it
is enjoyable”. Whilst 40 respondents (52%) agreed, or strongly agreed to the statement “I would opt
for chemotherapy treatment if my pet will live for an extra 12 months with chemotherapy”, although others
felt: “one year is not enough”. Forty-two percent of participants (45% female; 30% male) would elect
for chemotherapy if their pet was diagnosed with a malignant tumour knowing the potential benefits
of the treatment. This reduced to 35% (35% female; 40% male) when considering the side effects of
chemotherapy treatment. These participants generally believed the “benefits (of chemotherapy) outweigh
the side effects” “it (chemotherapy) will give the animal vital time” and “the side effects don’t appear to be
drastic”, “any cancer treatment should be available to animals”, “chemotherapy is a wonderful idea even with
limited knowledge”, with one commenting “anything is better than putting the animal to sleep”. In contrast,
respondents who would not elect for chemotherapy in their pet felt “that after seeing what it does to
a person, I am unsure as to how ethical it is to do this to an animal that doesn’t understand” and, “having seen
a relative undergo chemo, I would be less inclined to agree to chemo for my dogs”. When making a decision to
treat animals with CT, the use of prior knowledge obtained by the participants exerted an influential
impact on some respondents’ decision making: “after seeing what it does to humans, I don’t think it is
ethical”, “I would find it hard as my sister and niece have been through it”, “cancer is the lesser evil” and
“surgery is a quicker resolution”.
4. Discussion
Most of the participants had some experience of chemotherapy in humans and/or animals, which
appears to inform decision making when considering if they would elect to place a terminally ill pet
upon a course of chemotherapy. Previous experience has been identified to contribute to the decision
making process in human medicine [49–51]. The results here suggest that owners’ beliefs and prior
experience of chemotherapy, especially their perception of side effects over potential benefits of the
treatment, will influence their decision to use chemotherapy in their pets. It would be worthwhile for
veterinary teams to allocate time to fully understand owners’ historic experiences of chemotherapy as
these will influence the treatment regime selected.
Similar traits to those observed in human oncology patients and their carers appear to also
occur within animal owners. The majority of respondents believed their pet’s quality of life would
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improve post-chemotherapy but many (72%) overestimated average survival time post-treatment.
Fewer owners would have elected for chemotherapy if the result was a shorter 3-month extended
survival compared to a 12-month survival period for their pet, which suggests quality of life is a key
consideration in decision-making. However it should be noted that “agree” and “strongly agree”
responses were summed to obtain these figures, therefore the results may over represent the strength
of feeling of those who took part. Respondents also quantified the benefits of chemotherapy in terms
of the treatment being a cure rather a palliative intervention. These opinions mimic those found in
human cancer patients and their caregivers [28]. Human cancer patients have indicated a preference
to be fully informed before undertaking treatment to provide time to adapt to their diagnosis and
make a fully informed decision [52–54]. A similar approach would be advocated in pet owners as
proxy representatives of the animal, as our results suggest that owners consider what treatment
approach to adopt from their perspective rather than their pets. It is therefore also important to
eliminate any potential disconnect that exists between owners’ perception of the severity of side effects
and the reality of what to expect within chemotherapy regimens. Veterinary teams should ensure
their approach in terminal cases includes knowledge transfer of the fundamental characteristics and
effects of chemotherapy, with a clear focus on how an animal’s quality of life will be affected and the
likely incidence and expression of side effects, to enable owners to possess sufficient knowledge and
understanding to make a fully informed decision. Paradoxically in human chemotherapy, patients
who feel they have a good relationship with open communication with their clinician are at higher
risk of having unrealistic expectations of the long term benefits of chemotherapy [28]. Therefore,
it would be beneficial to integrate a period of reflection into the decision making process and perhaps
a multi-person approach is warranted to ensure clients engage with information transfer. Without
these opportunities, owners may select chemotherapy to facilitate more time with their pet, despite
a poor understanding of the impact of chemotherapy on the animal which could lead to increased
distress during treatment protocols and after the animal’s death akin to feelings observed in human
care givers post-bereavement [16].
The majority of respondents expected aspects of an animal’s quality of life to reduce during and
after a course of chemotherapy treatment, with pets sleeping more, being less playful and showing
reduced activity levels. Interestingly, despite 55% of respondents stating they were aware of the side
effects associated with chemotherapy in animals, most owners did not feel these side effects were
acceptable when judging a pet’s quality of life. Respondents also did not feel the common side effects of
chemotherapy (vomiting, diarrhoea and behavioural changes) would be acceptable, as well as wanting
affected animals to experience more good than bad days. Previous work [46] found that although
owners of animals undergoing chemotherapy were very perceptive of clinical changes they did not
recognise signs which represented a reduced quality of life, despite the same people prioritising quality
of life over extended life expectancies [17]. The results suggest a disconnect exists between owners’
expectations of what their pet’s quality of life should be during chemotherapy and what it is likely to
be. Similarly, most owners here equated the therapy with an extended survival time beyond average
life expectancies post diagnosis or that it represented a cure, commenting: “(chemotherapy) saves
them, extends life, is a cure, chemotherapy increases their quality of life, the benefits outweigh the side effects,
and having side effects for a short time and to live a lot longer and healthier is better”. A similar paradox occurs
within human oncology [16,28] with misconceptions of the clinical impact of chemotherapy (quality of
life and life expectancy) common amongst patients receiving palliative care and their care-givers. It is
imperative to note that chemotherapy can lengthen survival times and offer a better quality of life for
neoplastic animals, a concept that should not be lost in client-veterinary communication. Therefore it
is important that the veterinary team supporting decision making in owners and understand that such
paradoxes exist as they could potentially misinform a client’s judgement of a pet’s quality of life and
welfare, and the subsequent decision to not elect for chemotherapy or to agree to the treatment.
Quality of life assessments are key tools that can be used to benefit patients, clinicians, caregivers or
owners, and can inform the medical/veterinary therapeutic decision making process [55]. The majority
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of assessments are disease specific and tend to focus on clinical parameters [39]. Examples in human
medicine include the EuroQol [56], Sickness Impact Assessment (SIP) [57] and the SF-36 [58]. Readers
are recommended to refer to Vols et al. [29] and Belshaw et al. [40] for reviews of quality of life tools
used within veterinary medicine. Specific oncology quality of life assessment tools are also available
(for example: De Haes et al. [59]). There is general agreement that an effective quality of life assessment
should contain six fundamental dimensions [59]:
1. Physical functioning (physiological, biomechanical and neural parameters, and the ability to
perform routine tasks—quantitative assessment),
2. Psychological functioning (cognitive abilities, mental health status, mood and personality—
quantitative and qualitative assessment). It should be noted these facets are difficult to assess
within animals and general behavioral changes may need to be considered to provide a measure
of psychological function,
3. Social functioning (environmental interaction and relationships—qualitative assessment),
4. Role activities (motivation, communication, play and exercise—quantitative and qualitative assessment),
5. Overall life satisfaction (enjoyment and fulfilment—qualitative assessment), and,
6. Perception of health status (overall rating—quantitative and qualitative assessment).
The key goal of quality of life assessment as a tool to inform owners’ decision making prior to
electing for an animal to start chemotherapy treatment or during chemotherapy regimens, is the ability
of the assessment to quantify clinically meaningful changes. Clinically meaningful changes can be
defined as those which influence a patient’s management or that result in a reduction or improvement
in functionality, or an increase or decrease in clinical symptoms [55]. Interpretation of change can
in itself be challenging as it is difficult to quantify if a change in score of ±0.1 or ±1.0 equates to
a clinically meaningful change. In veterinary oncology, quality of life assessments are predominately
questionnaire based and rarely go beyond clinical parameters [47]. More work needs to be done to
define reliable and valid tools and parameters which capture the full repertoire of changes that occur
in an animal’s quality of life, specifically here with reference to the terminally ill oncology patient [17].
The development of effective quality of life assessments would provide a baseline measure to facilitate
comparison between individuals in the clinical environment. Additionally, quality of life assessments
should be used as a precursory tool to facilitate client-veterinary discussions over the prognosis and
treatment options available, and enable clients to make truly informed decisions whether selecting
palliative care or euthanasia [17]. Therefore, we would recommend that veterinary teams integrate
a quality of life assessment into the initial consultation process for the oncology patient and implement
regular quality of life assessments for the duration of their treatment to optimise animal welfare.
The study does have limitations as questionnaires cannot fully explore the complexity that
underpins the perception and feelings of the respondents surveyed. The results presented here
represent the views of this sample and their perception of chemotherapy as a treatment, and these
may not be an accurate representation of broader pet owners’ feelings and opinions. Further work
incorporating larger numbers would be warranted. Future research using focus groups, interviews
and case studies drawn from individuals who were or had experienced chemotherapy directly with
their pet is essential to gain a broader insight into the owner decision making process, owner views of
chemotherapy and its impact on pets, and the influences of the veterinary team upon this.
5. Conclusions
The veterinary team has a duty of care to their clients and their pets to ensure the full
complexities of oncology and chemotherapy are communicated during consultations. Prior experience
of chemotherapy appears to directly influence owner decision making when considering whether
to undertake a course of chemotherapy in a pet. Owners generally overestimated the impact of
chemotherapy on pet survival times post treatment potentially establishing false expectations which
could result in enhanced distress post bereavement. Owners rate pets’ quality of life as key when
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choosing whether to engage with chemotherapy, however this assessment appears focused on clinical
parameters and not functional tasks, personality expression or changes in behaviour. Based on the
results, veterinary teams involved with oncology consultations should establish if clients have prior
experience of cancer treatments and their expectations of survival time. Quality of life assessments
which evaluate patient health status via clinical parameters, physical, psychological and social function,
interaction and life satisfaction should also be implemented during initial oncology consultations and
conducted regularly during chemotherapy courses to inform client decision making and to safe guard
animal welfare.
Supplementary Materials: The following are available online at www.mdpi.com/2076-2615/7/3/18/s1,
Questionnaire Design.
Acknowledgments: We would like to thank the participants for engaging with our project.
Author Contributions: Project design, planning and data collection was undertaken by Jane Williams and Hollie
Marie Byrd. Data analysis, manuscript writing up and editing was performed by Jane Williams, Catherine Phillips
and Hollie Marie Byrd.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Adelstein, D.J.; Saxton, J.P.; Rybicki, L.A.; Esclamado, R.M.; Wood, B.G.; Strome, M.; Lavertu, P.; Lorenz, R.R.;
Carroll, M.A. Multiagent concurrent chemoradiotherapy for locoreginally advances squamous cell head and
neck cancer: Mature result from a single institution. J. Clin. Oncol. 2006, 24, 1064–1071. [CrossRef] [PubMed]
2. Wilkowski, R.; Thoma, M.; Weingandt, H.; Duhmke, E.; Heinemann, V. Chemoradiation for ductal pancreatic
carcinoma: Principles of combining chemotherapy with radiations, definition of target volume and radiation
dose. J. Pancreas 2005, 6, 216–230.
3. Rakovitch, E.; Tsao, M.; Ung, Y.; Pignol, J.P.; Cheung, P.; Chow, E. Comparison of the efficacy and acute
toxicity of weekly versus daily chemoradiotherapy for non-small-cell lung cancer: A meta-analysis. Int. J.
Radiat. Oncol. Biol. Phys. 2004, 58, 196–203. [CrossRef]
4. Macmillian Cancer Support. What Is Chemotherapy? Available online: Https://www.macmillan.org.uk/
information-and-support/treating/chemotherapy/chemotherapy-explained/what-is-chemotherapy.html
(accessed on 27 January 2016).
5. Wolfesberger, B.; Tonar, Z.; Fuchs-Baumgartinger, A.; Walter, I.; Skalicky, M.; Witter, K.; Thalhammer, J.G.;
Pagitz, M.; Kleiter, M. Angiogenic markers in canine lymphoma tissues do not predict survival times in
chemotherapy treated dogs. Res. Vet. Sci. 2012, 92, 444–450. [CrossRef] [PubMed]
6. Withrow, S.J. Why worry about cancer in pets? In Withrow and MacEwen’s Small Animal Clinical Oncology,
4th ed.; Withrow, S.J., Vail, D.M., Eds.; Saunders Elsevier: Philadelphia, PA, USA, 2007; pp. xv–xvii.
7. Dobson, J.M. Introduction: Cancer in cats and dogs. In BSAVA Manual of Canine and Feline Oncology, 3rd ed.;
Dobson, J.M., Duncan, B., Lascelles, X., Eds.; British Small Animal Veterinary Association: Guarantee, UK,
2011; pp. 1–5.
8. Animal Heath Trust Cancer Research. Available online: http://www.aht.org.uk/cms-display/science_
oncology.html (accessed on 20 January 2016).
9. International Cat Care. Cancer in Cats. Available online: http://icatcare.org/advice/cat-health/cancer-cats
(accessed on 20 January 2016).
10. Animal Cancer Trust. Types of Cancer. Available online: http://www.animalcancertrust.co.uk/types-of-
cancer (accessed on 2 March 2016).
11. Wang, S.L.; Lee, I.J.; Liao, A.T. Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in
combination of chemotherapy for canine lymphoma. Can. Vet. J. 2016, 57, 271–276. [PubMed]
12. Pirrone, F.; Pierantoni, L.; Mazzola, S.M.; Vigo, D.; Albertini, M. Owner and animal factors predict the
incidence of, and wner reaction towards, problematic behaviours in companion dogs. J. Vet. Behav. Clin.
Appl. Res. 2015, 10, 295–301. [CrossRef]
13. Arkow, P. Application of ethics to animal welfare. Appl. Anim. Behav. Sci. 1998, 59, 193–200.
Animals 2017, 7, 18 11 of 12
14. Royal College of Veterinary Surgeons. Communication and Consent. Available online: http://www.rcvs.org.
uk/advice-and-guidance/code-of-professional-conduct-for-veterinary-surgeons/supporting-guidance/
communication-and-consent (accessed on 27 January 2016).
15. Jacobs, H.H. Ethics in pediatric end-of-life care: A nursing perspective. J. Pediatr. Nurs. 2005, 20, 360–369.
[CrossRef] [PubMed]
16. Wright, A.L.; Zhang, B.; Keating, N.L.; Weeks, J.C.; Prigerson, H.G. Associations between palliative
chemotherapy and adult cancer patients’ end of life care and place of death: Prospective cohort study.
Br. Med. J. 2014. [CrossRef] [PubMed]
17. Giuffrida, M.A.; Kerrigan, S.M. Quality of life measurement in prospective studies of cancer treatments in
dogs and cats. J. Vet. Intern. Med. 2014, 28, 1824–1829. [CrossRef] [PubMed]
18. Macdonald, J.; Gray, C. “Informed consent”—How do we get it right? Vet. Nurs. J. 2014, 29, 101–103.
[CrossRef]
19. Wright, I.M. Complications and consent. Equine Vet. Educ. 2014, 26, 292–293. [CrossRef]
20. Panting, G. Informed consent. Orthop. Trauma 2010, 24, 441–446. [CrossRef]
21. Hamilton, A. Chemotherapy: What progress in the last 5 years? J. Clin. Oncol. 2005, 23, 1760–1775. [CrossRef]
[PubMed]
22. Cannon, C.; Borgatti, A.; Henson, M.; Husbands, B. Evaluation of a combination chemotherapy protocol
including lomustine and doxorubicin in canine histiocytic sarcoma. J. Small Anim. Pract. 2015, 56, 425–429.
[CrossRef] [PubMed]
23. Shapiro, W.; Fossum, T.W.; Kitchell, B.E.; Couto, C.G.; Theilen, G.H. Use of cisplatin for treatment of
appendicular osteosarcoma in dogs. J. Am. Vet. Med. Assoc. 1988, 192, 507–511. [PubMed]
24. Elliott, J.W.; Cripps, P.; Marrington, A.M.; Grant, I.A.; Blackwood, L. Epirubicin as part of a multi-agent
chemotherapy protocol for canine lymphoma. Vet. Comp. Oncol. 2013, 11, 185–198. [CrossRef] [PubMed]
25. Taylor, S.S.; Goodfellow, M.R.; Browne, W.J.; Walding, B.; Murphy, S.; Tzannes, S.; Gerou-Ferriani, M.;
Schwartz, A.; Dobson, J.M. Feline extranodal lymphoma: Response to chemotherapy and survival in 110
cats. J. Small Anim. Pract. 2009, 50, 584–592. [CrossRef] [PubMed]
26. McNeil, C.J.; Sorenmo, K.U.; Shofer, F.S.; Gibeon, L.; Durham, A.C.; Barber, L.G.; Baez, J.L.; Overley, B.
Evaluation of adjuvant doxorubicin-based chemotherapy for the treatment of feline mammary carcinoma.
J. Vet. Intern. Med. 2009, 23, 123–129. [CrossRef] [PubMed]
27. Wendelburg, K.M.; Price, L.L.; Burgess, K.E.; Lyons, J.A.; Lew, F.H.; Berg, J. Survival time of dogs with splenic
hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001–2012).
J. Am. Vet. Med. Assoc. 2015, 247, 393–403. [CrossRef] [PubMed]
28. Weeks, J.C.; Catalano, P.J.; Cronin, A.; Finkelman, M.D.; Mack, J.W.; Keating, N.L.; Schrag, D. Patients’
expectations about effects of chemotherapy for advanced cancer. N. Engl. J. Med. 2012, 367, 1616–1625.
[CrossRef] [PubMed]
29. Vols, K.K.; Heden, M.A.; Kristensen, A.T.; Sandoe, P. Quality of life assessment in dogs and cats receiving
chemotherapy—A review of current methods. Vet. Comp. Oncol. 2016. [CrossRef]
30. Boden, E.; Andrews, A. Black’s Veterinary Dictionary (Online); Bloomsbury: London, UK, 2015.
31. Shehadeh, N.J.; Ensley, J.F.; Kucuk, O.; Black, C.; Yoo, G.H.; Jacobs, J.; Lin, H.S.; Heilbrun, L.K.; Smith, D.;
Kim, H. Benefit of postoperative chemoradiotherapy for patients with unknown primary squamous cell
carcinoma of the head and neck. Head Neck 2006, 28, 1090–1098. [CrossRef] [PubMed]
32. Hume, K.R.; Johnson, J.L.; Williams, L.E. Adverse effects of concurrent carboplatin chemotherapy and
radiation therapy in dogs. J. Vet. Intern. Med. 2009, 23, 24–30. [CrossRef] [PubMed]
33. Morrow, G.R.; Roscoe, J.A.; Hickok, J.T.; Andrews, P.L.; Matteson, S. Nausea and emesis: Evidence for
a biobehavioural perspective. Support. Care Cancer 2002, 10, 96–105. [CrossRef] [PubMed]
34. Axiak-Bechtal, S.; Fowler, B.; Yu, D.H.; Amorim, J.; Tsuruta, K.; DeClue, A. Chemotherapy and remission
status do not alter pre-existing innate immune dysfunction in dogs with lymphoma. Res. Vet. Sci. 2014, 97,
230–237. [CrossRef] [PubMed]
35. Lane, A.E.; Black, M.L.; Wyatt, K.M. Toxicity and efficacy of a novel doxorubicin and carboplatin
chemotherapy protocol for the treatment of canine appendicular osteosarcoma following limb amputation.
Aust. Vet. J. 2012, 90, 69–74. [CrossRef] [PubMed]
36. Myers, J.S. Cancer and chemotherapy related cognitive changes: The patient experience. Semin. Oncol. Nurs.
2013, 29, 300–307. [CrossRef] [PubMed]
Animals 2017, 7, 18 12 of 12
37. Navari, R.M. 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.
Biochim. Biophys. Acta 2015, 1848, 2738–2746. [CrossRef] [PubMed]
38. Xenoulis, P.G. Nausea: Is it a big “little problem” in animals? Vet. J. 2015, 203, 267. [CrossRef] [PubMed]
39. Tzannes, S.; Hammond, M.F.; Murphy, S.; Sparks, A.; Blackwood, L. Owners perception of their cats quality
of life during COP chemotherapy for lymphoma. J. Feline Med. Surg. 2008, 10, 73–81. [CrossRef] [PubMed]
40. Belshaw, Z.; Asher, L.; Harvey, N.D.; Dean, R.S. Quality of life assessment in domestic dogs:
An evidence-based rapid review. Vet. J. 2015, 206, 203–212. [CrossRef] [PubMed]
41. Yeates, M.; Main, D. Assessment of companion animal quality of life in veterinary practice and research.
J. Small Anim. Pract. 2009, 50, 274–281. [CrossRef] [PubMed]
42. Lynch, S.; Savary-Bataille, K.; Leeuw, B.; Argyle, D.J. Development of a questionnaire assessing health-related
quality-of-life in dogs and cats with cancer. Vet. Comp. Oncol. 2010, 9, 172–182. [CrossRef] [PubMed]
43. Reynolds, C.A.; Oyama, M.A.; Rush, J.E.; Rozanski, E.A.; Singletary, G.E.; Brown, D.C.; Cunningham, S.M.;
Fox, P.R.; Bond, B.; Adin, D.B.; et al. Perceptions of quality of life and priorities of owners of cats with heart
disease. J. Vet. Intern. Med. 2010, 24, 1421–1426. [CrossRef] [PubMed]
44. Hamilton, M.J.; Sarcornrattana, O.; Illiopoulou, M.; Xie, Y.; Kitchell, B. Questionnaire-based assessment of
owner concerns and doctor responsiveness: 107 canine chemotherapy patients. J. Small Anim. Pract. 2012, 53,
627–633. [CrossRef] [PubMed]
45. Finlay, J.; Wyatt, K.; Black, M. Evaluation of the risks of chemotherapy in dogs with thrombocytopenia.
Vet. Comp. Oncol. 2017, 15, 151–162. [CrossRef] [PubMed]
46. Salmons, J. Doing Qualitative Research Online; Sage Publications: London, UK, 2016.
47. Bruce, I. Questionnaire Design How to Plan, Structure and Write Survey Material for Effective Market Research,
3rd ed.; Kogan Page Limited: New Delhi, India, 2013.
48. Charmaz, C. Constructing Grounded Theory: A Practical Guide through Qualitative Analysis; Sage Publications:
London, UK, 2006.
49. Li, S.Y.W.; Rakow, T.; Newell, B.R. Personal experience in doctor and patient decision making: From
psychology to medicine. J. Eval. Clin. Pract. 2009, 15, 993–995. [CrossRef] [PubMed]
50. Karimian, Z.; Kojuri, J.; Sagheb, M.M.; Mahboudi, A.; Saber, M.; Amini, M.; Dehghani, M.R. Comparison of
residents’ approaches to clinical decisions before and after the implementation of evidence based medicine
course. J. Adv. Med. Educ. Prof. 2013, 2, 170–175.
51. Roykenes, K. “My math and me”: Nursing students’ previous experiences in learning mathematics.
Nurse Educ. Pract. 2016, 16, 1–7. [CrossRef] [PubMed]
52. Wisk, T.M. Informed consent. Plast. Surg. Nurse 2006, 26, 203. [CrossRef]
53. Sinding, C.; Hudak, P.; Wiernikowski, J.; Aronson, J.; Miller, P.; Gould, J.; Fitzpatrick-Lewis, D. “I like to be
an informed person but...” negotiating responsibility for treatment decisions in cancer care. Soc. Sci. Med.
2010, 71, 1094–1101. [CrossRef] [PubMed]
54. Oostendorp, L.J.M.; Ottevanger, P.B.; Van De Wouw, A.J.; Honkoop, A.H.; Los, M.; Van Der Graaf, W.T.A.;
Stalmeier, P.F.M. Patients’ preferences for information about the benefits and risks of second-line palliative
chemotherapy and their oncologist’s awareness of these preferences. J. Cancer Educ. 2016, 31, 443–448.
[CrossRef] [PubMed]
55. Crosby, R.D.; Kalotkin, R.L.; Williams, R. Defining clinically meaningful change in health related quality of
life. J. Clin. Epidemiol. 2003, 56, 395–407. [CrossRef]
56. Brooks, R. EuroQoL the current state of play. Health Policy 1996, 37, 53–72. [CrossRef]
57. Bergner, M.; Bobbit, R.A.; Carter, C.A. The sickness impact profile: Development and final revision of a health
status measure. Med. Care 1981, 19, 787–803. [CrossRef] [PubMed]
58. Ware, J.E.; Sherbourne, C.D. The MOS short form health survey (SF-36). Med. Care 1992, 30, 473–483.
[CrossRef] [PubMed]
59. De Haes, J.L.J.M.; Olscheski, M.; Fayers, P.M. Measuring Quality of Life of Cancer Patients with the Rotterdam
Symptom Checklist (RSCL): A Manual; Groningen Northern Centre for Health Care Research: Groningen,
The Netherlands, 1996.
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
